KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Current Assets: 2019-2025

Historic Current Assets for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to $1.8 billion.

  • Royalty Pharma's Current Assets rose 3.08% to $1.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year increase of 3.08%. This contributed to the annual value of $1.8 billion for FY2024, which is 41.43% up from last year.
  • As of Q3 2025, Royalty Pharma's Current Assets stood at $1.8 billion, which was up 21.66% from $1.5 billion recorded in Q2 2025.
  • Over the past 5 years, Royalty Pharma's Current Assets peaked at $3.5 billion during Q2 2022, and registered a low of $1.3 billion during Q4 2023.
  • Its 3-year average for Current Assets is $2.0 billion, with a median of $1.8 billion in 2024.
  • Per our database at Business Quant, Royalty Pharma's Current Assets tumbled by 50.13% in 2023 and then soared by 41.43% in 2024.
  • Over the past 5 years, Royalty Pharma's Current Assets (Quarterly) stood at $2.9 billion in 2021, then dropped by 11.23% to $2.6 billion in 2022, then tumbled by 50.13% to $1.3 billion in 2023, then spiked by 41.43% to $1.8 billion in 2024, then climbed by 3.08% to $1.8 billion in 2025.
  • Its Current Assets was $1.8 billion in Q3 2025, compared to $1.5 billion in Q2 2025 and $1.8 billion in Q1 2025.